{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T11:44:04Z","timestamp":1794915844424,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MEXT KAKENHI","award":["JP22520907"],"award-info":[{"award-number":["JP22520907"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Clinical scenario 1 (CS1) is acute heart failure (HF) characterized by transient systolic blood pressure (SBP) elevation and pulmonary congestion. Although it is managed by vasodilators, the molecular mechanism remains unclear. The sympathetic nervous system plays a key role in HF, and desensitization of cardiac \u03b2-adrenergic receptor (AR) signaling due to G protein-coupled receptor kinase 2 (GRK2) upregulation is known. However, vascular \u03b2-AR signaling that regulates cardiac afterload remains unelucidated in HF. We hypothesized that upregulation of vascular GRK2 leads to pathological conditions similar to CS1. GRK2 was overexpressed in vascular smooth muscle (VSM) of normal adult male mice by peritoneally injected adeno-associated viral vectors driven by the myosin heavy chain 11 promoter. Upregulation of GRK2 in VSM of GRK2 overexpressing mice augmented the absolute increase in SBP (+\u200922.5\u2009\u00b1\u20094.3\u00a0mmHg vs.\u2009+\u200936.0\u2009\u00b1\u20094.0\u00a0mmHg, P\u2009&lt;\u20090.01) and lung wet weight (4.28\u2009\u00b1\u20090.05\u00a0mg\/g vs. 4.76\u2009\u00b1\u20090.15\u00a0mg\/g, P\u2009&lt;\u20090.01) by epinephrine as compared to those in control mice. Additionally, the expression of brain natriuretic peptide mRNA was doubled in GRK2 overexpressing mice as compared to that in control mice (P\u2009&lt;\u20090.05). These findings were similar to CS1. GRK2 overexpression in VSM may cause inappropriate hypertension and HF, as in CS1.<\/jats:p>","DOI":"10.1038\/s41598-023-34209-5","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T06:02:57Z","timestamp":1683871377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Overexpression of GRK2 in vascular smooth muscle leads to inappropriate hypertension and acute heart failure as in clinical scenario 1"],"prefix":"10.1038","volume":"13","author":[{"given":"Hiroki","family":"Yano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Onoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Tokinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Ioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuki","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Seno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"34209_CR1","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jchf.2021.05.009","volume":"9","author":"SM Dunlay","year":"2021","unstructured":"Dunlay, S. M. et al. Advanced heart failure epidemiology and outcomes: A population-based study. JACC Heart Fail. 9, 722\u2013732 (2021).","journal-title":"JACC Heart Fail."},{"key":"34209_CR2","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski, P. et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 37, 2129\u20132200m (2016).","journal-title":"Eur. Heart J."},{"key":"34209_CR3","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1161\/CIRCULATIONAHA.107.690768","volume":"116","author":"IC Sarwat","year":"2007","unstructured":"Sarwat, I. C., Yongfei, W., John, C., Thomas, M. G. & Harlan, M. K. Patterns of weight change preceding hospitalization for heart failure. Circulation 116, 1549\u20131554 (2007).","journal-title":"Circulation"},{"key":"34209_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejheart.2008.01.007","volume":"10","author":"G Cotter","year":"2008","unstructured":"Cotter, G., Metra, M., Milo-Cotter, O., Dittrich, H. C. & Gheorghiade, M. Fluid overload in acute heart failure - Re-distribution and other mechanisms beyond fluid accumulation. Eur. J. Heart Fail. 10, 165\u2013169 (2008).","journal-title":"Eur. J. Heart Fail."},{"key":"34209_CR5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1161\/CIRCHEARTFAILURE.111.961789","volume":"4","author":"C Fallick","year":"2011","unstructured":"Fallick, C., Sobotka, P. A. & Dunlap, M. E. Sympathetically mediated changes in capacitance redistribution of the venous reservoir as a cause of decompensation. Circ. Heart Fail. 4, 669\u2013675 (2011).","journal-title":"Circ. Heart Fail."},{"key":"34209_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1388-9842(02)00017-X","volume":"4","author":"G Cotter","year":"2002","unstructured":"Cotter, G. et al. Acute heart failure: A novel approach to its pathogenesis and treatment. Eur. J. Heart Fail. 4, 227\u2013234 (2002).","journal-title":"Eur. J. Heart Fail."},{"key":"34209_CR7","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1097\/01.CCM.0000296274.51933.4C","volume":"36","author":"A Mebazaa","year":"2008","unstructured":"Mebazaa, A. et al. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit. Care Med. 36, S129\u2013S139 (2008).","journal-title":"Crit. Care Med."},{"key":"34209_CR8","doi-asserted-by":"publisher","first-page":"9A","DOI":"10.1016\/0002-9149(85)90790-8","volume":"55","author":"WW Parmley","year":"1985","unstructured":"Parmley, W. W. Pathophysiology of congestive heart failure. Am. J. Cardiol. 55, 9A-14A (1985).","journal-title":"Am. J. Cardiol."},{"key":"34209_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1253\/jcj.44.117","volume":"44","author":"K Bito","year":"1980","unstructured":"Bito, K., Kubo, S. & Saimyoji, H. Role of endocrine factors in chronic congestive heart failure, with emphasis on catecholamines. Jpn. Circ. J. 44, 117\u2013127 (1980).","journal-title":"Jpn. Circ. J."},{"key":"34209_CR10","first-page":"1796","volume":"46","author":"CS Alain","year":"2005","unstructured":"Alain, C. S. et al. Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure. J. Nucl. Med. 46, 1796\u20131803 (2005).","journal-title":"J. Nucl. Med."},{"key":"34209_CR11","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1161\/01.CIR.0000141297.50027.A4","volume":"110","author":"MR Bristow","year":"2004","unstructured":"Bristow, M. R. et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the \u03b2-blocker evaluation of survival trial. Circulation 110, 1437\u20131442 (2004).","journal-title":"Circulation"},{"key":"34209_CR12","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1054-3589(08)60777-2","volume":"42","author":"RJ Lefkowitz","year":"1998","unstructured":"Lefkowitz, R. J., Pitcher, J., Krueger, K. & Daaka, Y. Mechanisms of \u03b2-adrenergic receptor desensitization and resensitization. Adv. Pharmacol. 42, 416\u2013420 (1998).","journal-title":"Adv. Pharmacol."},{"key":"34209_CR13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1146\/annurev.biochem.67.1.653","volume":"67","author":"JA Pitcher","year":"1998","unstructured":"Pitcher, J. A., Freedman, N. J. & Lefkowitz, R. J. G protein-coupled receptor kinases. Annu. Rev. Biochem. 67, 653\u2013692 (1998).","journal-title":"Annu. Rev. Biochem."},{"key":"34209_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1161\/CIRCHEARTFAILURE.112.966895","volume":"5","author":"G Rengo","year":"2012","unstructured":"Rengo, G. et al. Targeting the \u03b2-adrenergic receptor system through G-protein-coupled receptor kinase 2: A new paradigm for therapy and prognostic evaluation in heart failure from bench to bedside giuseppe rengo pasquale perrone-filardi. Circ. Heart Fail. 5, 385\u2013391 (2012).","journal-title":"Circ. Heart Fail."},{"key":"34209_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/BF00563002","volume":"18","author":"TL Svendsen","year":"1980","unstructured":"Svendsen, T. L., Hartling, O. J. & Trap-Jensen, J. Immediate haemodynamic effects of prenalterol, a new adrenergic beta-1-receptor agonist, in healthy volunteers. Eur. J. Clin. Pharmacol. 18, 219\u2013223 (1980).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"34209_CR16","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1172\/JCI107237","volume":"52","author":"G Bodem","year":"1973","unstructured":"Bodem, G., Brammell, H. L., Weil, J. V. & Chidsey, C. A. Pharmacodynamic studies of beta adrenergic antagonism induced in man by propranolol and practolol. J. Clin. Investig. 52, 747\u2013754 (1973).","journal-title":"J. Clin. Investig."},{"key":"34209_CR17","doi-asserted-by":"publisher","first-page":"e66195","DOI":"10.1371\/journal.pone.0066195","volume":"8","author":"DR Annette","year":"2013","unstructured":"Annette, D. R. et al. Levosimendan relaxes pulmonary arteries and veins in precision-cut lung slices - the role of KATP-channels, cAMP and cGMP. PLoS One 8, e66195 (2013).","journal-title":"PLoS One"},{"key":"34209_CR18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.yexcr.2018.01.032","volume":"363","author":"A Xue","year":"2018","unstructured":"Xue, A. et al. Aberrant endoplasmic reticulum stress mediates coronary artery spasm through regulating MLCK\/MLC2 pathway. Exp. Cell Res. 363, 321\u2013331 (2018).","journal-title":"Exp. Cell Res."},{"key":"34209_CR19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ando.2020.03.012","volume":"82","author":"J Motiejunaite","year":"2021","unstructured":"Motiejunaite, J., Amar, L. & Vidal-Petiot, E. Adrenergic receptors and cardiovascular effects of catecholamines. Ann. Endocrinol. (Paris) 82, 193\u2013197 (2021).","journal-title":"Ann. Endocrinol. (Paris)"},{"key":"34209_CR20","doi-asserted-by":"publisher","first-page":"16694","DOI":"10.1074\/jbc.274.24.16694","volume":"274","author":"AJ Chruscinski","year":"1999","unstructured":"Chruscinski, A. J. et al. Targeted disruption of the \u03b22 adrenergic receptor gene. J. Biol. Chem. 274, 16694\u201316700 (1999).","journal-title":"J. Biol. Chem."},{"key":"34209_CR21","doi-asserted-by":"publisher","first-page":"16701","DOI":"10.1074\/jbc.274.24.16701","volume":"274","author":"DK Rohrer","year":"1999","unstructured":"Rohrer, D. K., Chruscinski, A., Schauble, E. H., Bernstein, D. & Kobilka, B. K. Cardiovascular and metabolic alterations in mice lacking both \u03b21- and \u03b22-adrenergic receptors. J. Biol. Chem. 274, 16701\u201316708 (1999).","journal-title":"J. Biol. Chem."},{"key":"34209_CR22","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/0092-8674(93)80042-D","volume":"74","author":"RJ Lefkowitz","year":"1993","unstructured":"Lefkowitz, R. J. G protein-coupled receptor kinases minireview a novel family of receptor kinases. Cell 74, 409\u2013412 (1993).","journal-title":"Cell"},{"key":"34209_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev.physiol.62.1.237","volume":"62","author":"WJ Koch","year":"2000","unstructured":"Koch, W. J., Lefkowitz, R. J. & Rockman, H. A. Functional consequences of altering myocardial adrenergic receptor signaling. Annu. Rev. Physiol. 62, 237\u2013260 (2000).","journal-title":"Annu. Rev. Physiol."},{"key":"34209_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/01.RES.86.1.43","volume":"86","author":"AD Eckhart","year":"2000","unstructured":"Eckhart, A. D. et al. Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. Circ. Res. 86, 43\u201350 (2000).","journal-title":"Circ. Res."},{"key":"34209_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0009-9236(99)70074-3","volume":"65","author":"R Gros","year":"1999","unstructured":"Gros, R. et al. G-protein-coupled receptor kinase expression in hypertension. Clin. Pharmacol. Ther. 65, 545\u2013551 (1999).","journal-title":"Clin. Pharmacol. Ther."},{"key":"34209_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1161\/01.HYP.35.1.38","volume":"35","author":"R Gros","year":"2000","unstructured":"Gros, R. et al. G-protein\u2013coupled receptor kinase activity in hypertension. Hypertension 35, 38\u201342 (2000).","journal-title":"Hypertension"},{"key":"34209_CR27","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1172\/JCI114487","volume":"85","author":"RD Feldman","year":"1990","unstructured":"Feldman, R. D. Defective venous beta-adrenergic response in borderline hypertensive subjects is corrected by a low sodium diet. J. Clin. Investig. 85, 647\u2013652 (1990).","journal-title":"J. Clin. Investig."},{"key":"34209_CR28","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1124\/mol.61.4.749","volume":"61","author":"AD Eckhart","year":"2002","unstructured":"Eckhart, A. D., Ozaki, T., Tevaearai, H., Rockman, H. A. & Koch, W. J. Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates \u03b2-adrenergic receptor signaling and increases resting blood pressure. Mol. Pharmacol. 61, 749\u2013758 (2002).","journal-title":"Mol. Pharmacol."},{"key":"34209_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1046\/j.1440-1681.2002.03625.x","volume":"29","author":"N Dzimiri","year":"2002","unstructured":"Dzimiri, N., Basco, C., Moorji, A., Afrane, B. & Al-Halees, Z. Characterization of lymphocyte \u03b22-adrenoceptor signalling in patients with left ventricular volume overload disease. Clin. Exp. Pharmacol. Physiol. 29, 181\u2013188 (2002).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"34209_CR30","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1161\/CIRCRESAHA.115.308207","volume":"118","author":"G Rengo","year":"2016","unstructured":"Rengo, G. et al. Prognostic value of lymphocyte G protein-coupled receptor kinase-2 protein levels in patients with heart failure. Circ. Res. 118, 1116\u20131124 (2016).","journal-title":"Circ. Res."},{"key":"34209_CR31","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1152\/ajpregu.2001.280.3.R897","volume":"280","author":"WE Schutzer","year":"2001","unstructured":"Schutzer, W. E., Reed, J. F., Bliziotes, M. & Mader, S. L. Upregulation of G protein-linked receptor kinases with advancing age in rat aorta. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280, 897\u2013903 (2001).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"34209_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.vph.2011.09.001","volume":"55","author":"WE Schutzer","year":"2011","unstructured":"Schutzer, W. E. et al. Age-related \u03b2-adrenergic receptor-mediated vasorelaxation is changed by altering G protein receptor kinase 2 expression. Vascul. Pharmacol. 55, 178\u2013188 (2011).","journal-title":"Vascul. Pharmacol."},{"key":"34209_CR33","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1042\/cs0600571","volume":"60","author":"P Van Brummelen","year":"1981","unstructured":"Van Brummelen, P., Buhler, F. R., Kiowski, W. & Amann, F. W. Age related decrease in cardiac and peripheral vascular responsiveness to isoprenaline: Studies in normal subjects. Clin. Sci. 60, 571\u2013577 (1981).","journal-title":"Clin. Sci."},{"key":"34209_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000212317","volume":"25","author":"C Strozzi","year":"1979","unstructured":"Strozzi, C. et al. Disorders in peripheral arterial system in asymptomatic elderly: Plethysmographie semiology at rest, during postural, effort and pharmacological tests. Gerontology 25, 24\u201335 (1979).","journal-title":"Gerontology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34209-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34209-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34209-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T06:16:03Z","timestamp":1683872163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-34209-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["34209"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-34209-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2313136\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"25 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Saito Y. has received research funds from Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Bristol-Myers Squibb Company, Actelion Pharmaceuticals Japan Ltd., Kyowa Kirin Co., Ltd., Kowa Pharmaceutical Co., Ltd, Shionogi & Co., Ltd, Dainippon Sumitomo Pharma Co., Ltd., Teijin Pharma Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Nihon Medi-Physics Co., Ltd., Novartis Pharma K.K., Pfizer Japan Inc. and Fuji Yakuhin Co., Ltd., research expences from Novartis Pharma K.K., Roche Diagnostics K.K., Amgen Inc., Bayer Yakuhin, Ltd., Astellas Pharma Inc. and Actelion Pharmaceuticals Japan Ltd., speakers\u2019 bureau\/honorarium from Alnylam Japan K.K., AstraZeneca K.K., Otsuka Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd, Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Tsumura & Co., Teijin Pharma Ltd., Toa Eiyo Ltd., Nippon Shinyaku Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Bayer Yakuhin Ltd., Pfizer Japan Inc., Bristol-Myers Squibb Company and Mochida Pharmaceutical Co., Ltd., consultation fees from Ono Pharmatical Co., Ltd. and Novartis Pharma K.K.; Other authors have no disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7707"}}